证券代码：920662 证券简称：方盛股份 公告编号：2026-017 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 特别提示：本公告所载 2025 年 年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 386,423,474.05 | 347,167,424.95 | 11.31% | | 利润总额 | 21,513,434.70 | 33,155,307.32 | -35.11% | | 归属于上市公司股 | 19,469,250.99 | 29,808,798.02 | -34.69% | | 东的净利润 | | | | | 归属于上市公司股 | 17,196,398.36 | 25,825,111.23 ...

证券代码：920062 证券简称：科润智控 公告编号：2026-012 科润智能控制股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会计师事 务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投资者注意投资 风险。 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 1,426,600,919.16 | 1,347,620,535.10 | 5.86% | | 利润总额 | 12,614,044.72 | 45,072,613.66 | -72.01% | | 归属于上市公司股东的净利润 | 15,914,038.03 | 42,862,185.93 | -62.87% | | 归属于上市公司股东的扣除非经常 | 3,116,062.63 | 38,0 ...

证券代码：920953 证券简称：国子软件 公告编号：2026-005 山东国子软件股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 报告期内，公司营业收入较上年同期增长 22.15%，主要是公司持续加大市 场拓展力度，深耕现有客户，积极开拓新市场，且取得了一定的销售成果；在业 绩增长的同时，公司净利润也实现了同比小幅增长。 报告期末，公司股本较期初增长 39.40%，主要是公司 2025 年实施 2024 年 年度权益分派方案，向参与分派的股东每 10 股转增 4 股所致。 当前，公司主营业务发展稳健，客户服务体系持续优化，新客户拓展亦取得 积极进展，整体经营面保持稳定。面向未来，公司将持续强化技术创新与服务升 级，提升运营效率，力争在复杂多变的市场环 ...

Financial Performance - The total operating revenue for 2025 was CNY 154.56 million, an increase of 8.11% compared to the previous year[4] - The operating profit was CNY -220.56 million, with a loss increase of CNY 23.82 million year-on-year[7] - The net profit attributable to shareholders of the parent company was CNY -222.46 million, an increase in loss of CNY 29.23 million compared to the previous year[7] - The basic earnings per share were CNY -1.25, compared to CNY -1.08 in the previous year[4] - The weighted average return on net assets was -28.49%, a decrease of 9.04 percentage points year-on-year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 1,299.42 million, a decrease of 14.59% from the beginning of the period[4] - The equity attributable to shareholders of the parent company was CNY 674.83 million, down 24.36% from the beginning of the period[4] Expenses and Investments - The company increased its investment in market expansion, technology research and development, and talent development, leading to high expense levels[8] - The increase in credit impairment losses was due to extended collection periods influenced by client budget adjustments and funding delays[9] - The company made provisions for asset impairments, including inventory and fixed assets, impacting the current period's profit[11]

Financial Performance - The company achieved total operating revenue of 801.14 million yuan in 2025, representing a 122.60% increase compared to the previous year[3] - The net loss attributable to the parent company was 763.31 million yuan, a reduction of 82.65 million yuan from the previous year's loss[7] - The company's total assets increased by 74.69% to 3.00 billion yuan, while equity attributable to the parent company surged by 568.16% to 1.29 billion yuan[3] - The weighted average return on net assets improved to -73.92%, up from -161.12% in the previous year, indicating a positive trend in financial performance[3] Research and Development - Research and development expenses for the year amounted to 855.61 million yuan, reflecting the company's commitment to innovation[8] - The company is actively expanding the application potential of its commercialized products, with ongoing clinical trials for Shuwozhe® and Gaoruizhe® in NSCLC[12] Product Development and Approval - The company successfully launched two products, Shuwozhe® and Gaoruizhe®, which were included in the national medical insurance directory, significantly enhancing patient accessibility[6] - Shuwozhe® received FDA approval for treating adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, marking a significant milestone in the company's product portfolio[9] - The company’s subsidiary obtained a drug production license, ensuring qualifications for future commercial production[12] Capital and Liquidity - The company raised 1.773 billion yuan through a private placement of shares, significantly boosting its liquidity and capital reserves[7]

证券代码：688052 证券简称：纳芯微 公告编号：2026-011 苏州纳芯微电子股份有限公司 2025 年年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 报告期内，公司营业收入同比增长 71.80%，主要得益于以下两方面：（1） 下游汽车电子领域需求稳健增长，公司汽车电子领域相关产品持续放量；泛能源 领域整体呈复苏态势，其中光伏和储能领域大部分客户恢复正常需求，服务器电 源客户需求在 AI 驱动下增长迅速；（2）麦歌恩并表丰富了公司产品矩阵，其业 务贡献对本期营收增长形成积极影响。 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 336,782.31 | 196,027.42 | 71.80 | | ...

Financial Performance - Total revenue for 2025 reached RMB 2,152,918,524.19, an increase of 5.39% compared to RMB 2,042,835,394.88 in the previous year[2] - The net profit attributable to shareholders of the parent company was a loss of RMB 58,307,472.09, a reduction in loss of 70.53% year-on-year from a loss of RMB 197,849,927.16[2] - The basic earnings per share for the period was -0.57, reflecting a year-on-year improvement of 70.62% from -1.94[2] - The equity attributable to shareholders of the parent company decreased by 5.22% to RMB 2,378,285,239.99 from RMB 2,509,210,485.75[2] Operational Efficiency - The company's gross profit margin improved while sales, research and management expense ratios decreased, leading to a significant reduction in operating losses[6] - The company reported a significant increase in operating cash flow, indicating improved operational efficiency[5] Strategic Focus - The company focused on its core business and implemented the "DAS" strategy, leading to rapid growth in key areas such as AI and cybersecurity[4] - Subscription-based revenue continued to grow, maintaining a positive growth trend during the reporting period[4] Asset Management - The total assets at the end of the reporting period were RMB 4,491,761,885.36, a decrease of 10.80% from RMB 5,035,768,395.71 at the beginning of the period[2] - The company conducted impairment tests on certain assets, which impacted the current period's performance[6]

证券代码：688306 证券简称：均普智能 公告编号:2026-020 宁波均普智能制造股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以宁波均普智能制造股份有限公司（以下简称"公司"）2025年年度报 告中披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 1 单位：人民币万元 项目 本报告期 上年同期 增减变动幅度（％） 营业总收入 257,990.35 266,171.51 -3.07 营业利润 1,316.09 2,178.09 -39.58 利润总额 1,392.13 2,144.37 -35.08 归属于母公司所有者的 净利润 1,219.48 819.77 48.76 归属于母公司所有者的 扣除非经常性损益的净 利润 671.33 -1,639.29 不适用 基本每股收益（元） 0.0100 0.0067 49.25 加权平均净资产收益率 0 ...

Financial Performance - Total operating revenue for 2025 reached CNY 2,565,911.35 million, a year-on-year increase of 1.04%[2] - Net profit attributable to shareholders decreased by 16.74% to CNY 88,881.09 million, while net profit excluding non-recurring gains and losses increased by 20.08% to CNY 51,264.37 million[2][4] - Operating profit fell by 32.45% compared to the previous year, primarily due to price declines in urea and polyvinyl chloride, as well as decreased coal prices[6] - Basic earnings per share decreased by 18.05% to CNY 0.8188[2] Assets and Equity - Total assets at the end of the reporting period were CNY 4,595,153.53 million, reflecting a growth of 3.84% from the beginning of the period[2][4] - Shareholders' equity attributable to the company decreased by 18.81% to CNY 688,128.81 million[2][4] Strategic Initiatives - The company is actively responding to market fluctuations and is focusing on upgrading traditional industries and launching major projects such as phosphate chemical projects[5] - The company has successfully integrated Xinjiang Yihua Chemical Co., optimizing its product structure and promoting transformation and upgrading[6] Reporting and Forecasts - The company did not provide prior earnings forecasts for 2025[7] - The financial data presented is preliminary and subject to final audit, with potential discrepancies in the annual report[8]

Financial Performance - The company achieved total operating revenue of 516.56 million yuan, representing a year-on-year growth of 21.99%[3] - The net profit attributable to shareholders of the parent company was -57.51 million yuan, compared to -46.73 million yuan in the same period last year[3] - The basic earnings per share were -0.68 yuan, compared to -0.55 yuan in the previous year[3] - The weighted average return on net assets improved to -3.96%, an increase of 0.66 percentage points[3] Assets and Equity - Total assets increased to 2,340.34 million yuan, up 7.00% from the beginning of the reporting period[5] - Equity attributable to the parent company reached 1,025.51 million yuan, a growth of 4.34% compared to the beginning of the reporting period[4] Operational Developments - The company continued to expand its new energy powertrain testing service capabilities, contributing to revenue growth[5] - The company anticipates future profitability as production and testing scales increase, which will dilute fixed costs[5] Expenses - R&D expenses were maintained at a high level, while financial expenses decreased due to foreign exchange gains[5] Cautionary Note - The company warns investors to be cautious as the financial data is preliminary and unaudited[7]